News
SPRO
1.225
-0.41%
-0.005
Weekly Report: what happened at SPRO last week (0803-0807)?
Weekly Report · 1d ago
Weekly Report: what happened at SPRO last week (0727-0731)?
Weekly Report · 08/03 09:43
Catalyst Watch: Jobs report, SpaceX's first report, AMD, and SK Hynix ratings
Seeking Alpha · 07/31 19:00
Spero Therapeutics Names Debra Jeske Zack As Chief Medical Officer
NASDAQ · 07/27 13:02
Press Release: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Dow Jones · 07/27 12:00
Weekly Report: what happened at SPRO last week (0720-0724)?
Weekly Report · 07/27 09:45
Big Tech Earnings, Fed's Interest Rate Decision To Keep Next Week Busy
Seeking Alpha · 07/25 15:00
Weekly Report: what happened at SPRO last week (0713-0717)?
Weekly Report · 07/20 09:43
Spero Therapeutics inks major CD40L and royalty deals
TipRanks · 07/15 08:11
Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Bln
Dow Jones · 07/15 06:48
Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing
Seeking Alpha · 07/14 17:40
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 07/14 17:05
Spero gets ex-China rights to Innovent’s antibody therapy for up to $1.1B
Seeking Alpha · 07/14 12:28
At a glance: stocks gapping down premarket
Seeking Alpha · 07/14 10:56
Innovent Grants Spero Ex-China Rights To Anti-CD40L Antibody IBI355 In Up To $1.1 Bln Deal
NASDAQ · 07/14 10:38
Spero Announces Royalty Financing Deal With Affiliates Of Healthcare Royalty
NASDAQ · 07/14 10:38
Spero inks $105M financing deal with KKR affiliate
Seeking Alpha · 07/14 10:33
Spero Therapeutics secures $105M non-dilutive financing to develop SP001
TipRanks · 07/14 10:15
Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty
Benzinga · 07/14 10:11
Spero Therapeutics, Innovent Biologics enter license agreement for SP001
TipRanks · 07/14 10:11
More
Webull provides a variety of real-time SPRO stock news. You can receive the latest news about Spero Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.